User profiles for Neil A. Segal
 | Neil SegalProfessor, Rehabilitation Medicine, University of Kansas Verified email at kumc.edu Cited by 9928 |
[HTML][HTML] Nivolumab plus ipilimumab in advanced melanoma
Background In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte–associated
antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody …
antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody …
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
[HTML][HTML] Immunotherapy in colorectal cancer: rationale, challenges and potential
Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a subset …
established as a major treatment modality for multiple types of solid cancers, including a subset …
[HTML][HTML] Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy
Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed
death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, …
death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, …
[HTML][HTML] Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy
PURPOSE Prospective data on the efficacy of a watch-and-wait strategy to achieve organ
preservation in patients with locally advanced rectal cancer treated with total neoadjuvant …
preservation in patients with locally advanced rectal cancer treated with total neoadjuvant …
[HTML][HTML] Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial …
…, JA Blake-Haskins, A Gupta, NH Segal - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose To investigate the safety and efficacy of durvalumab, a human monoclonal antibody
that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on …
that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on …
The effects of Pilates training on flexibility and body composition: an observational study
NA Segal, J Hein, JR Basford - Archives of physical medicine and …, 2004 - Elsevier
Segal NA, Hein J, Basford JR. The effects of Pilates training on flexibility and body composition:
an observational study. Arch Phys Med Rehabil 2004;85:1977–81. OBJECTIVE: To …
an observational study. Arch Phys Med Rehabil 2004;85:1977–81. OBJECTIVE: To …
[PDF][PDF] Clinical sequencing defines the genomic landscape of metastatic colorectal cancer
Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis
of this variability remains poorly understood. We performed prospective targeted sequencing …
of this variability remains poorly understood. We performed prospective targeted sequencing …
Greater trochanteric pain syndrome: epidemiology and associated factors
… Author links open overlay panel Neil A. Segal MD a , David T. Felson MD b , James C. …
Segal NA, Felson DT, Torner JC, Zhu Y, Curtis JR, Niu J, Nevitt MC, for the Multicenter …
Segal NA, Felson DT, Torner JC, Zhu Y, Curtis JR, Niu J, Nevitt MC, for the Multicenter …
Epitope landscape in breast and colorectal cancer
The finding that individual cancers contain many mutant genes not present in normal tissues
has prompted considerable interest in the cancer epitope landscape. To further understand …
has prompted considerable interest in the cancer epitope landscape. To further understand …